Superior Planning, LLC’s 4D Molecular Therapeutics FDMT Stock Holding History

Superior Planning, LLC’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.53K	Buy	+526	New	+$6.84K	﹤0.01%	1042

Other funds holding FDMT

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

Superior Planning, LLC's FDMT Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in 4D Molecular Therapeutics (FDMT) in Q3 2026: 526 shares worth $7.53K. The stake represents ﹤0.01% of the portfolio and ranks #1042 among its holdings.

82 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

Superior Planning, LLC held 526 shares of 4D Molecular Therapeutics worth $7.53K as of Q3 2026.
4D Molecular Therapeutics was a new Superior Planning, LLC position in Q3 2026.
4D Molecular Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1042 holding.
82 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.